Core Insights - GH Research PLC shares increased by 18.1% to $15.64 in pre-market trading following the announcement of an update on its FDA IND status and Phase 3 program for GH001 in treatment-resistant depression [1] Gainers - MKDWELL Tech Inc surged 61.2% to $0.27 after agreeing to repurchase 34,580,000 ordinary shares at $0.203/share, totaling $7 million [4] - Regencell Bioscience Holdings Ltd gained 52% to $31.21 after a previous decline of 2% [4] - Datavault AI Inc rose 26.7% to $1.28 after a 55% increase on the previous trading day [4] - Sidus Space Inc increased by 21.9% to $5.28 following a 38% rise on Friday [4] - Kazia Therapeutics Ltd rose 21.7% to $6.08 after a 27% decline on Friday [4] - Context Therapeutics Inc gained 18.7% to $1.84 after a 5% increase on Friday [4] - Hyperscale Data Inc rose 18.6% to $0.32 after a 49% jump on Friday [4] - PBF Energy Inc increased by 16.7% to $33.30 after providing updates on Martinez refinery operations and 2026 annual guidance [4] - Bioatla Inc rose 16.1% to $0.62 after a dip of more than 5% on Friday [4] Losers - Salarius Pharmaceuticals Inc fell 21.8% to $0.51 in pre-market trading [4] - Gain Therapeutics Inc decreased by 21.4% to $2.50 [4] - SBC Medical Group Holdings Inc declined 18.9% to $3.51 [4] - Polyrizon Ltd dropped 11.7% to $11.24 after a 50% gain on Friday [4] - ChowChow Cloud International HLDG Ltd dipped 10.3% to $0.71 after a 30% increase on Friday [4] - Lavoro Ltd shares fell 9.1% to $1.00 after a 144% jump on Friday [4] - Vicarious Surgical Inc decreased by 7.9% to $2.32 after a 16% gain on Friday [4] - Theravance Biopharma Inc dipped 6% to $17.07 after a 3% decline on Friday [4] - Comcast Corp tumbled 4.6% to $28.18 [4] - Equinor ASA fell 3.6% to $23.66 after a 4% increase on Friday [4]

Group 1: Market Overview - Several high-volatility healthcare and cannabis stocks experienced sharp after-hours gains despite a quiet news day, driven by recent catalysts and technical momentum [1] Group 2: Tilray Brands, Inc. (TLRY) - Tilray's stock rose by 11.36% after hours, reaching $13.53, following a one-for-ten reverse stock split effective December 1, and had already increased by 44.13% during the day [2] Group 3: Valneva SE (VALN) - Valneva's shares increased by 7.22% after hours to $9.31, recovering from a 3.45% decline earlier in the day, supported by positive data from its Phase 2 chikungunya vaccine trial [3] Group 4: Chemomab Therapeutics Ltd. (CMMB) - Chemomab's stock rose by 7.66% after hours to $2.39, reacting to results from its Phase 2 SPRING trial published in the American Journal of Gastroenterology [4] Group 5: Genenta Science S.p.A. (GNTA) - Genenta's shares climbed by 12.06% after hours to $1.58, rebounding from a 14.5% drop, following updated data from its TEM-GBM study in glioblastoma patients [5] Group 6: Kazia Therapeutics Limited (KZIA) - Kazia's stock increased by 10.93% after hours to $11.57, recovering from a 20% decline, after presenting new evidence for its PI3K/mTOR inhibitor at the 2025 SABCS [6] Group 7: Traws Pharma, Inc. (TRAW) - Traws Pharma's shares edged up by 8.81% after hours to $2.54, maintaining active trading momentum despite no new developments [7]

Energy Sector - Constellation secured a $1 billion loan from the U.S. Department of Energy to advance its Crane Clean Energy Center, which aims to bring 835 MW of new baseload nuclear power online [2][3] - The funding is part of the Energy Dominance Financing Program and is expected to lower Constellation's cost of capital, supporting infrastructure for the digital economy and increasing power capacity for AI workloads [3][4] Technology Sector - Adobe announced its acquisition of Semrush for $12.00 per share, valuing the company at approximately $1.9 billion, marking a significant move in digital marketing [10][20] - The acquisition aims to enhance Adobe's customer experience orchestration capabilities in the context of generative AI, addressing challenges in brand visibility and engagement [11][12] Oncology Sector - Kazia Therapeutics reported a patient with stage IV triple-negative breast cancer achieved an initial immune-complete response under an expanded-access protocol, a notable outcome given the low response rates in such cases [6][7] - The company highlighted its plans for upcoming presentations and progress in its drug development pipeline, including a request for a Type C meeting with the FDA [9]

Core Viewpoint - Kazia Therapeutics Limited has sold all intellectual property and trademark rights to its oncology drug candidate Cantrixil to Vivesto for USD $1 million, providing non-dilutive funding to advance its clinical-stage pipeline [1][3]. Group 1: Transaction Details - Kazia will receive USD $1 million from Vivesto for the rights to Cantrixil [1]. - Vivesto had previously licensed exclusive global development and commercialization rights for Cantrixil from Kazia in March 2021 [2]. - Vivesto has decided not to pursue Cantrixil for ovarian cancer and is now exploring it for hematological cancers [2]. Group 2: Company Overview - Kazia Therapeutics is an oncology-focused drug development company based in Sydney, Australia, with a lead program, paxalisib, targeting multiple forms of brain cancer [4]. - Paxalisib has undergone ten clinical trials and has received various designations from the FDA, including Orphan Drug Designation and Fast Track Designation for glioblastoma [4]. - The company is also developing EVT801, a small molecule inhibitor of VEGFR3, which has shown activity against a broad range of tumor types [4].